中国肠外肠内营养学的转化医学3T路线图概述

Brief Review of the 3T's Roadmap of Translational Medicine for Parenteral and Enteral Nutrition in China

截至2020年,中国肠外肠内营养学已经历从实验室研究到临床应用(Translation 1,T1)、大样本临床有效性研究(Translation 2,T2),分步进入测算医疗质量及成本-效果(Translation 3,T3)的发展时期。中华医学会肠外肠内营养学分会营养风险-不足-支持-结局-成本效果比多中心分享数据库协作组借鉴国际转化医学3T路线图,在中国开拓了肠外肠内营养学领域的T3阶段转化研究,包括卫生经济学研究。目前,中国肠外肠内营养学领域需开展“合理应用,患者受益”有关的临床研究,如营养风险筛查及营养不良诊断的临床有效性研究,以及营养用药有关的卫生经济学研究。

Till 2020,parenteral and enteral nutrition in China has moved from Translation 1(T1),and then Translation 2(T2),to Translation 3(T3)now.The T3 transfer requires the evaluation of medical services’quality and cost-effectiveness research.After learning from international published articles,the multicenter cooperative database group of Chinese Society for Parenteral and Enteral Nutrition(CSPEN)on Nutritional risk,Undernutrition,Support,Outcome,and Cost-effectiveness ratio(NUSOC)(abbreviated to CSPEN-NUSOC Cooperative Group)has made efforts to promote health economics research in the field of parenteral and enteral nutrition in China.This paper reviewed the translational medical research of parenteral and enteral nutrition in China.At present,clinical studies toward the goal of“reasonable use to benefit patients”should be conducted in parenteral and enteral nutrition field in China,such as clinical effectiveness study of nutritional risk screening 2002 and Global Leadership Initiative on Malnutrition criteria,or health economics study on nutritional drug.